Hoth Therapeutics (HOTH) Expected to Announce Earnings on Friday

Hoth Therapeutics (NASDAQ:HOTH) is anticipated to issue its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.1031) per share for the quarter.

Hoth Therapeutics Trading Down 6.7%

Shares of NASDAQ:HOTH opened at $0.92 on Friday. The stock’s fifty day simple moving average is $1.00 and its two-hundred day simple moving average is $1.22. Hoth Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.12. The stock has a market cap of $14.32 million, a PE ratio of -0.87 and a beta of 0.50.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HOTH. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Hoth Therapeutics to a “sell” rating in a report on Saturday, March 7th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Wednesday, March 4th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. DRW Securities LLC purchased a new stake in shares of Hoth Therapeutics during the 4th quarter valued at $257,000. Geode Capital Management LLC boosted its holdings in shares of Hoth Therapeutics by 18.0% in the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after buying an additional 27,577 shares during the last quarter. Citadel Advisors LLC bought a new position in Hoth Therapeutics during the third quarter valued at about $232,000. Virtu Financial LLC bought a new position in Hoth Therapeutics during the third quarter valued at about $184,000. Finally, Kestra Private Wealth Services LLC purchased a new stake in Hoth Therapeutics during the third quarter worth about $51,000. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.